[HTML][HTML] Phase 2 trial of baxdrostat for treatment-resistant hypertension
MW Freeman, YD Halvorsen, W Marshall… - … England Journal of …, 2023 - Mass Medical Soc
Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …
pharmacologic target for the treatment of hypertension for several decades. Selective …
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
MW Freeman, YD Halvorsen, W Marshall… - The New England …, 2022 - europepmc.org
Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …
pharmacologic target for the treatment of hypertension for several decades. Selective …
[引用][C] Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
MWW Freeman, YD Halvorsen, W Marshall… - NEW ENGLAND …, 2023 - qmro.qmul.ac.uk
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension Toggle navigation Login
Toggle navigation Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension QMRO …
Toggle navigation Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension QMRO …
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
MW Freeman, YD Halvorsen… - The New England …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …
pharmacologic target for the treatment of hypertension for several decades. Selective …
Phase 2 trial of baxdrostat for treatment-resistant hypertension
MW Freeman - search.ebscohost.com
This was a prespecified secondary analysis of an ongoing trial that had randomised 4869
critically ill adult patients with COVID-19 to interventions within six treatment domains …
critically ill adult patients with COVID-19 to interventions within six treatment domains …